Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun YN, Parasrampuria DA. Luo MM, et al. Among authors: touzeau c. J Clin Pharmacol. 2021 May;61(5):614-627. doi: 10.1002/jcph.1771. Epub 2020 Nov 3. J Clin Pharmacol. 2021. PMID: 33145788 Free PMC article.
Elotuzumab for the treatment of multiple myeloma.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Future Oncol. 2014 May;10(6):949-56. doi: 10.2217/fon.14.56. Future Oncol. 2014. PMID: 24941981 Review.
Multiple myeloma: from front-line to relapsed therapies.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Am Soc Clin Oncol Educ Book. 2015:e504-11. doi: 10.14694/EdBook_AM.2015.35.e504. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993216 Free article. Review.
The role of SLAMF7 in multiple myeloma: impact on therapy.
Boudreault JS, Touzeau C, Moreau P. Boudreault JS, et al. Among authors: touzeau c. Expert Rev Clin Immunol. 2017 Jan;13(1):67-75. doi: 10.1080/1744666X.2016.1209112. Epub 2016 Jul 18. Expert Rev Clin Immunol. 2017. PMID: 27376202 Review.
Daratumumab for the treatment of multiple myeloma.
Touzeau C, Moreau P. Touzeau C, et al. Expert Opin Biol Ther. 2017 Jul;17(7):887-893. doi: 10.1080/14712598.2017.1322578. Epub 2017 May 2. Expert Opin Biol Ther. 2017. PMID: 28434255 Review.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P. Moreau P, et al. Among authors: touzeau c. Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Lancet. 2019. PMID: 31171419 Clinical Trial.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C. Chari A, et al. Among authors: touzeau c. Br J Haematol. 2021 Mar;192(5):869-878. doi: 10.1111/bjh.16980. Epub 2020 Jul 30. Br J Haematol. 2021. PMID: 33216361 Free article.
181 results